User profiles for Joseph P. Sanderson

Joseph Sanderson

Senior Director, Preclinical Research, Adaptimmune Ltd
Verified email at soton.ac.uk
Cited by 1417

Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals

…, M Brigl, EY Kim, A Tuli, JP Sanderson… - Nature …, 2011 - nature.com
Invariant natural killer T cells (iNKT cells) have a prominent role during infection and other
inflammatory processes, and these cells can be activated through their T cell antigen …

[HTML][HTML] Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

…, P Kebriaei, Q Lin, AJ Tipping, JP Sanderson… - Nature medicine, 2023 - nature.com
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy.
Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell …

Activation of T cells by carbamazepine and carbamazepine metabolites

Y Wu, JP Sanderson, J Farrell, NS Drummond… - Journal of allergy and …, 2006 - Elsevier
… Author links open overlay panel Ying Wu BSc a , Joseph P. Sanderson BSc a , John Farrell
BSc a , Nicola S. Drummond PhD a , Anita Hanson BSc a , Elizabeth Bowkett BSc b , Neil …

Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling

JP Sanderson, DJ Naisbitt, J Farrell… - The Journal of …, 2007 - journals.aai.org
Different signals in addition to the antigenic signal are required to initiate an immunological
reaction. In the context of sulfamethoxazole allergy, the Ag is thought to be derived from its …

[HTML][HTML] An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

…, LU Weigand, M Canestraro, JP Sanderson… - PloS one, 2018 - journals.plos.org
Robust preclinical testing is essential to predict clinical safety and efficacy and provide data
to determine safe dose for first-in-man studies. There are a growing number of examples …

Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy

JP Sanderson, DJ Crowley, GE Wiedermann… - …, 2020 - Taylor & Francis
A substantial obstacle to the success of adoptive T cell-based cancer immunotherapy is the
sub-optimal affinity of T-cell receptors (TCRs) for most tumor antigens. Genetically …

Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate

EC Border, JP Sanderson, T Weissensteiner… - …, 2019 - Taylor & Francis
Circulating T-cells that have passed thymic selection generally bear T-cell receptors (TCRs)
with sub-optimal affinity for cancer-associated antigens, resulting in a limited ability to detect …

[PDF][PDF] Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer

RY Docta, T Ferronha, JP Sanderson… - …, 2019 - Wiley Online Library
Patients with hepatocellular carcinoma (HCC) have a poor prognosis and limited therapeutic
options. Alpha‐fetoprotein (AFP) is often expressed at high levels in HCC and is an …

β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis

…, J Farrell, J Hamlett, JP Sanderson… - Chemical research in …, 2013 - ACS Publications
β-Lactam antibiotics provide the cornerstone of treatment for respiratory exacerbations in
patients with cystic fibrosis. Unfortunately, approximately 20% of patients develop multiple …

[HTML][HTML] Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

…, D Batrakou, MM Pentony, JP Sanderson… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10)
are genetically engineered autologous T cells that express a high-affinity melanoma-…